← Back to Search

Dronabinol for HIV/AIDS

Phase 1

Recruiting

Led By Ke Xu, MD, PhD

Research Sponsored by Yale University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

HIV-positive on antiretroviral therapy.

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline, 120 minutes post-dronabinol and 360 minutes post-dronabinol, up 5 years

Awards & highlights

No Placebo-Only Group

Summary

This trial seeks to understand how cannabis affects people living with HIV and its effects on the immune system. Results could inform policy and new treatments.

Who is the study for?

This trial is for adults with HIV/AIDS who currently use or have used cannabis, are on antiretroviral therapy, and have a low viral load. They must be in good health overall and women able to bear children should agree to use birth control during the study.

What is being tested?

The study tests Dronabinol Capsules to understand their effects on immune function and inflammation in people with HIV who consume cannabis. It will explore if these effects depend on one's HIV status, potentially guiding future treatments.

What are the potential side effects?

While not explicitly listed here, Dronabinol may cause dizziness, mood changes, headaches, confusion or memory impairment; however individual experiences can vary.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am HIV-positive and on antiretroviral therapy.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline, 120 minutes post-dronabinol and 360 minutes post-dronabinol, up 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline, 120 minutes post-dronabinol and 360 minutes post-dronabinol, up 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, 120 minutes post-dronabinol and 360 minutes post-dronabinol, up 5 years for reporting.